QTc prolongation after receiving intravenous or intramuscular haloperidol injection for the management of acute agitation in hospitalized psychiatric patients intravenous haloperidol intramuscular haloperidol QTc prolongation QTc prolongation cardiotoxicity electrocardiography psychiatric patients antipsychotics antipsychotic medication acute agitation aggression
Conditions
Interventions
The patients received intravenous haloperidol injection as clinically indicated for managing acute agitation and underwent evaluation of QTc prolongation by ECG 30 minutes after injection.,The patient
Treatment,Treatment
IVH,IMH
Sponsors
Research Unit Buddhachinaraj Phitsanulok Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Acute agitated psychiatric in-patients aged older than 18 years 2. The patients received intravenous or intramuscular haloperidol injection as clinically indicated for managing acute agitation
Exclusion criteria
Exclusion criteria: 1. No baseline ECG recording 2. Patients with delirium due to another medical condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QTc prolongation in 30 mins after haloperidol injection QTc interval measurements on ECG were evaluated by 2 cardiologists. | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactTiyarat Kayankit
Buddhachinaraj Phitsanulok Hospital
Outcome results
None listed